title: Clinical experience with the Omnicarbon prosthetic heart valve.
abstract: The Omnicarbon prosthetic heart valve (Medical Inc., Inver Grove Heights, Minn.) was implanted in 124 patients (mean age 53 +/- 11 years); 66 of them had aortic valve replacement, 40 had mitral valve replacement, and 18 had both aortic and mitral valve replacement. Preoperatively 76.6% were in New York Heart Association class 3 or 4, and 84.7% were in class 1 or 2 after the operation. There were six (4.8%) early deaths and seven late deaths. Survival was 85% +/- 6% at 6 years in the aortic valve replacement group, 94% +/- 4% at 3 years in the mitral valve replacement group, and 78% +/- 11% at 4 years in the double valve replacement group. Freedom from cardiac death was 89% +/- 4% at 6 years (2.0% per patient-year) in the aortic valve replacement group, 94% +/- 4% at 3 years (1.8% per patient-year) in the mitral valve replacement group, and 78% +/- 11% at 4 years (5.7% per patient-year) in the double valve replacement group. There were six valve-related complications. Freedom from valve-related complications was 92% +/- 4% at 6 years (1.5% per patient-year) in the aortic valve replacement group, 97% +/- 3% at 3 years (1.8% per patient-year) in the mitral valve replacement group, and 83% +/- 11% at 4 years (5.7% per patient-year) in the double valve replacement group. Cerebral hemorrhage was seen in two patients in the aortic valve replacement group. Freedom from all events was 80% +/- 7% at 6 years in the aortic valve replacement group, 88% +/- 6% at 3 years in the mitral valve replacement group, and 78% +/- 11% at 4 years in the double valve replacement group. Elevation of the postoperative serum lactate dehydrogenase levels was minimal in all groups. The maximum opening angle at rest was 60.0 +/- 8.9 degrees in the aortic position and 54.1 +/- 6.6 degrees in the mitral position. In conclusion, the Omnicarbon prosthesis had excellent postoperative clinical status and negligible hemolysis.
authors.affiliation: Department of Thoracic and Cardiovascular Surgery, Jichi Medical School, Tochigi, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Misawa
authors.forename: T
authors.initials: T
authors.lastname: Hasegawa
authors.forename: M
authors.initials: M
authors.lastname: Kato
mesh_terms: D000328:Adult; D001021:Aortic Valve; D005260:Female; D005500:Follow-Up Studies; D006349:Heart Valve Diseases / Q000145:classification / Q000401:mortality / Q000601:surgery*; D006350:Heart Valve Prosthesis / Q000145:classification / Q000592:standards*; D006785:Hospitals, University; D006801:Humans; D007564:Japan / Q000453:epidemiology; D007770:L-Lactate Dehydrogenase / Q000097:blood; D008297:Male; D008875:Middle Aged; D008943:Mitral Valve; D011183:Postoperative Complications / Q000453:epidemiology / Q000209:etiology; D012307:Risk Factors; D012720:Severity of Illness Index; D015996:Survival Rate
chemical_list: D007770:L-Lactate Dehydrogenase